How Analysts Feel About Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB) After Increase in Sellers?

January 14, 2018 - By wolcottdaily

 How Analysts Feel About Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB) After Increase in Sellers?

The stock of Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB) registered an increase of 10.58% in short interest. CATB’s total short interest was 240,400 shares in January as published by FINRA. Its up 10.58% from 217,400 shares, reported previously. With 231,200 shares average volume, it will take short sellers 1 days to cover their CATB’s short positions. The short interest to Catabasis Pharmaceuticals Incorporated’s float is 2.3%.

The stock decreased 1.28% or $0.02 during the last trading session, reaching $1.54. About 274,447 shares traded or 1.63% up from the average. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has declined 73.74% since January 14, 2017 and is downtrending. It has underperformed by 90.44% the S&P500.

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted linker drug discovery platform in the United States. The company has market cap of $35.55 million. The firm offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD). It currently has negative earnings. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Ratings Coverage

Among 5 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Catabasis Pharmaceuticals had 14 analyst reports since August 17, 2015 according to SRatingsIntel. Cowen & Co maintained the stock with “Hold” rating in Thursday, October 5 report. The rating was maintained by Wedbush on Monday, August 14 with “Buy”. Oppenheimer maintained Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) on Monday, August 14 with “Buy” rating. On Monday, November 20 the stock rating was upgraded by Citigroup to “Buy”. On Tuesday, March 22 the stock rating was maintained by Citigroup with “Buy”. The rating was maintained by Cowen & Co with “Hold” on Thursday, August 10. H.C. Wainwright maintained it with “Buy” rating and $9.2900 target in Monday, August 14 report. The stock of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) earned “Neutral” rating by Citigroup on Thursday, October 5. Wedbush maintained the stock with “Buy” rating in Monday, August 17 report. H.C. Wainwright initiated Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) rating on Thursday, December 22. H.C. Wainwright has “Buy” rating and $14 target.

More notable recent Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) news were published by: Seekingalpha.com which released: “Catabasis Pharmaceuticals’ (CATB) CEO Jill Milne on Q1 2017 Results – Earnings …” on May 12, 2017, also Businesswire.com with their article: “Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to …” published on October 04, 2017, Seekingalpha.com published: “Catabasis Pharmaceuticals Could Be A Strong Investment Opportunity In 2017” on April 12, 2017. More interesting news about Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) were released by: Businesswire.com and their article: “Annual Piper Jaffray Healthcare Conference” published on November 21, 2017 as well as Seekingalpha.com‘s news article titled: “Catabasis Pharmaceuticals’ (CATB) CEO Jill Milne on Q2 2017 Results – Earnings …” with publication date: August 11, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.